Kaplan Matthew L. 4

What Happened
Matthew L. Kaplan, a director of Nuvectis Pharma, was granted 35,000 shares of restricted common stock on 2026-06-11 (transaction reported on Form 4 filed 2026-06-12). The grant is recorded at $0.00 per share on the Form 4; total cash value is shown as $0 because this is an award/compensation grant, not a market purchase.

Key Details

• Transaction type: A (award/grant) — 35,000 restricted shares acquired on 2026-06-11 at $0.00 per share.
• Filing: Form 4 filed 2026-06-12 covering the 2026-06-11 transaction (appears timely).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: F1 — the 35,000 shares vest in equal annual installments over three years beginning on the first anniversary of the grant date, subject to continued board service. F2 — these are restricted common stock.

Context
This was a service-based equity award to a director rather than an open-market purchase or sale. Restricted shares vest over time and typically cannot be sold until vested (and subject to the company’s restrictions), so the grant does not represent an immediate market purchase or sale by the insider.